InvestmentPitch Media Video Discusses LOVE Pharma’s Strategic Investment in Starton Therapeutics, a New Jersey Based Clinical Stage Biotechnology Company
Retrieved on:
Thursday, September 8, 2022
CBD, CEO, CSE, OTC, Female, Time-invariant system, Therapy, Awareness, Nausea, OLZ, Tongue, US, LLD, R & D, FSE, Hygiene, STAR, Pfizer, Patent, LOVE, DOC, GLOBE, FDA, Biotechnology, Lubrication, Suggestion, News, Pharma, Risk, Lenalidomide, CDN, Clinical trial, Industry, Vomiting, Fine chemical, Pharmaceutical industry
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has made a strategic investment in Starton Therapeutics Inc., a New Jersey based clinical stage biotechnology company focused on transforming standard of care therapies in oncology.
Key Points:
- VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has made a strategic investment in Starton Therapeutics Inc., a New Jersey based clinical stage biotechnology company focused on transforming standard of care therapies in oncology.
- A Media Snippet accompanying this announcement is available by clicking on the image or link below:
For more information, please view the InvestmentPitch Media video, which provides additional information about this news and the company. - If these links are not enabled, please visit www.InvestmentPitch.com and enter Love Pharma in the search box.
- The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.